Posts Tagged: "IPWatchdog Webinars"

At first blush, the notion of who is an inventor, author, creator, or owner of an intangible asset is a relatively straightforward question. Federal law sets forth, in broad strokes, the basic parameters governing those issues. What is not so clearly defined, however, is who actually qualifies to be a joint inventor or joint author based on any unique set of…

What lies ahead for the US economy remains uncertain as economists warn of an imminent recession. Companies are beginning to buckle down and preparing to respond in predictable and obvious ways as they look internally to find cost-savings opportunities. But there are better ways to save than the all too familiar across-the-board cuts. For IP-centric organizations, assessing your own patents…

United States Patent and Trademark Office (USPTO) Acting Deputy Under Secretary of Commerce for Intellectual Property and Acting Deputy Director, Drew Hirshfeld, will step down from a nearly 30-year career with the Office on June 21, 2022. That very same day, Drew Hirshfeld will join Gene Quinn, President & CEO of IPWatchdog, Inc., for a conversation to take a look back at…

Section 145 of the Patent Act authorizes patent applicants to bring suit against the United States Patent and Trademark Office (USPTO) in district court following a loss at the Patent Trial and Appeal Board (PTAB). Under Section 145, patent applicants can present new evidence that was not suitable in a Patent Office appeal, including expert testimony. A 145 action can…

Communications between the C-suite and IP counsel can be layered with misunderstanding and peril. How can IP teams get the resources they need to do the job they are tasked with doing if the C-suite doesn’t understand what it is that the IP department is actually delivering for the company, or even capable of delivering for the company? Too often…

In this special 90-minute webinar, we will speak to in-house lawyers from some of the most innovative companies in the world. The panelists were chosen from companies identified in the “Innovation Momentum 2022: The Global Top 100” report by LexisNexis Intellectual Property Solutions. The report uncovers forward-thinking innovative companies that leverage the patent system to realize innovation momentum. The unique…

Over the past 80 years, approximately 40% of all FDA-approved pharmaceutical products have been in the form of pharmaceutical salts. The typical route for claiming such salts in patents involves claim cascades beginning with the ubiquitous “and pharmaceutically acceptable salts thereof” and often ends by naming the salt species of interest. Examples of such salts include sodium or hydrochloride salts…

The story of hold-up has seduced many who believe patents stand in the way of innovation, but what product or service has ever been held up by patent owners, or patent wars? Even in the area of smartphones or telecommunications, we can reliably predict that next year’s technology will be superior to this year’s technology, as devices and the services…

For many years Boolean Logic has been the gold standard for searching for patents and invention disclosures, and for some it still is.  But as every patent professional knows, Boolean Logic, as good as it is, has significant limitations. Indeed, relevant content necessary to make accurate evaluations can often be excluded from even the most intensive searches. Enter artificial intelligence…

Gene therapy, after years of promise, is now a reality, and monoclonal antibody pharmaceuticals are on the rise. Diagnostic testing is a necessary and standard part of medical practice. Outside of medicine, agricultural biotechnology improves our food supply. And even though Jurassic-Park-like dinosaur revival is still a dream, customized animals and revival of extinct species are a focus of real…

Online marketplaces, such as Amazon.com, provide brands unprecedented growth opportunities, but also give a similar advantage to brand competitors by offering an inexpensive and easy forum to market copycat, counterfeit, or infringing products. U.S. patent rights are traditionally enforced in federal courts or through International Trade Commission investigations, but these enforcement strategies can be slow and expensive, and deploying them…

One of the major challenges when licensing, transacting, or managing Standard Essential Patents (SEPs) is that there is no public database that provides information about verified SEPs. Standard-setting organizations (SSOs) such as ETSI (4G / 5G), IEEE (Wi-Fi), or ITUT (HEVC/VVC) maintain databases of so-called self-declared patents that are required to be licensed pursuant to a fair, reasonable and non-discriminatory…

Over the past 80 years, about 40% of all FDA-approved pharmaceutical products have been in the form of pharmaceutical salts. The typical route for claiming such salts in patents involves claim cascades beginning with the ubiquitous “and pharmaceutically acceptable salts thereof” and often ends by naming the particular salt species of interest. Examples of such salts include sodium or hydrochloride…

The value of intangible assets has reached staggering levels. By some estimates, as much as 90% of S&P valuation is attributed to intangible assets. With this increase in intangible assets valuation, companies and employees have become mindful of the need to extract value wherever possible. Still, for a variety of reasons the role of IP Manager can be difficult, with…